Photo: Franco Vogt/Getty Images

照片：Franco Vogt/Getty Images

Drug distributor Cencora has entered into a definitive agreement to acquire Retina Consultants of America, a management services organization (MSO) of retina specialists, from Webster Equity Partners for $4.6 billion.

药物分销商Cencora已达成最终协议，以46亿美元的价格从Webster Equity Partners收购视网膜专家管理服务组织Retina Consultants of America。

Cencora President and CEO Bob Mauch said in a statement that the acquisition will allow the company to broaden its relationships with community providers and place it at the forefront of retinal care.

Cencora总裁兼首席执行官鲍勃·莫赫（BobMauch）在一份声明中表示，此次收购将使该公司扩大与社区提供者的关系，并将其置于视网膜护理的前沿。

'We intend to use our leading operational infrastructure to help RCA enhance the provider experience, drive innovative new research and create better outcomes for patients,' said Mauch, adding that Cencora will now be able to expand its MSO solutions.

Mauch说：“我们打算利用我们领先的运营基础设施，帮助RCA提高提供者的体验，推动创新的新研究，并为患者创造更好的结果。”他补充说，Cencora现在将能够扩展其MSO解决方案。

RCA's affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally, Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal year 2027 and fiscal year 2028, subject to the successful completion of certain business objectives..

RCA的附属机构、医生和管理层将保留RCA的少数股权，Cencora在交割时持有RCA约85%的所有权。此外，Cencora可能会在2027财年和2028财年支付总计5亿美元的或有对价，前提是成功完成某些业务目标。。

Upon closing, the acquisition of RCA is expected to be approximately $0.35 accretive, net of estimated financing costs, to Cencora's adjusted diluted EPS for its first twelve months. Cencora plans to fund the transaction through a combination of existing cash on hand and new debt financing.

交易结束后，预计RCA的收购额将增加约0.35美元，扣除预计融资成本，达到Cencora前12个月调整后的稀释每股收益。Cencora计划通过现有库存现金和新债务融资的组合为交易提供资金。

WHAT'S THE IMPACT?

影响是什么？

The proposed transaction is expected to add to Cencora's capabilities in Specialty and expand its MSO business, broadening physician and manufacturer relationships as well as Cencora's value proposition to stakeholders.

拟议的交易有望增加Cencora的专业能力，扩大其MSO业务，扩大医生和制造商的关系，以及Cencora对利益相关者的价值主张。

Cencora expects to use its suite of manufacturer services to enhance RCA's research program and outcomes. RCA operates a clinical research network with 40 clinical trial sites spanning Phases I-IV and 400 full-time research employees.

Cencora预计将使用其一套制造商服务来增强RCA的研究计划和成果。RCA运营着一个临床研究网络，拥有40个跨越I-IV期的临床试验地点和400名全职研究人员。

Cencora's fiscal year 2025 guidance does not currently include the impact of the RCA acquisition, which will be incorporated following the transaction's close.

Cencora的2025财年指南目前不包括RCA收购的影响，该收购将在交易结束后纳入。

THE LARGER TREND

更大的趋势

Walgreens Boots Alliance sold its remaining shares of Cencora in August for $818 million.

沃尔格林靴子联盟（WalgreensBoots Alliance）8月份以8.18亿美元出售了其剩余的Cencora股份。

Proceeds will be used primarily for debt paydown and general corporate purposes, as the company continues to build out a more capital-efficient health services strategy rooted in its retail pharmacy footprint, Walgreens said.

沃尔格林表示，随着该公司继续建立一个植根于零售药店足迹的更具资本效率的医疗服务战略，收益将主要用于偿还债务和一般企业用途。

ON THE RECORD

记录在案

'We are pleased to enter our next phase of growth with the support of a leading global pharmaceutical solutions organization,' said RCA CEO Dr. Robby Grabow. 'With additional resources to support the continued execution of our growth strategy, we will be better positioned to continue expanding our physician network and enhancing the quality of care we provide.'.

有了额外的资源来支持我们继续执行增长战略，我们将能够更好地继续扩大我们的医生网络，提高我们提供的护理质量。”。

Jeff Lagasse is editor of Healthcare Finance News.Email: jlagasse@himss.orgHealthcare Finance News is a HIMSS Media publication.

杰夫·拉加西是《医疗保健金融新闻》的编辑。电子邮件：jlagasse@himss.orgHealthcare《财经新闻》是HIMSS的媒体出版物。